

AMENDMENTS TO THE CLAIMS

This listing of the claims replaces all prior versions, and listings, of claims in the Application. Please amend the claims as follows:

1. (Previously Presented) A pharmaceutical composition comprising a therapeutically effective amount of a combination of secretin and oxytocin.
- 2-7. (Canceled)
8. (Previously Presented) The pharmaceutical composition of claim 1 wherein the pharmaceutical composition includes one or more protease inhibitors.
- 9-16. (Canceled)
17. (Previously presented) A kit comprising the pharmaceutical composition of claim 1.
- 18-20. (Canceled)
21. (Previously Presented) The kit of claim 17, wherein the kit includes one or more protease inhibitors.
- 22-23. (Canceled)
24. (New) A method for treating a gastrointestinal disorder in a subject, comprising administering to the subject a therapeutically effective amount of secretin and a therapeutically effective amount of oxytocin.
25. (New) The method of claim 24, wherein the gastrointestinal disorder is selected from the group consisting of irritable bowel disease, irritable bowel syndrome, diarrhea, incontinence,

pelvic floor pain, biliary disorders, abdominal bloating colitis, constipation and gastrodueodenal disorders.

26. (New) A method for treating irritable bowel disease in a subject, comprising administering to the subject a therapeutically effective amount of secretin and a therapeutically effective amount of oxytocin.
27. (New) A method for treating a central nervous system disorder in a subject, comprising administering to the subject a therapeutically effective amount of secretin and a therapeutically effective amount of oxytocin.
28. (New) The method of claim 27, wherein the central nervous system disorder is selected from the group consisting of autism and autistic spectrum disorders, seizures, conduct disorder, oppositional defiant disorder (ODD), attentional/arousal dysregulation, attention-deficit/hyperactivity disorder (ADHD), obsessive-compulsive disorder, stereotypies, reactive attachment disorder, social isolation, attachment disorders, face recognition deficits, gaze aversions, and altered heart rate variability.
29. (New) A method for treating an autoimmune disorder in a subject, comprising administering to the subject a therapeutically effective amount of secretin and a therapeutically effective amount of oxytocin.
30. (New) The method of claim 29, wherein the autoimmune disorder is selected from the group consisting of Hashimoto's thyroiditis, pernicious anemia, scleroderma, anti-phospholipid syndrome, autoimmune inner ear disease, Behcet's syndrome, chronic inflammatory polyneuritis, CREST syndrome, Churg Strauss Syndrome, Guillain-Barre syndrome, Goodpasture's syndrome, primary biliary cirrhosis, Crohn's disease, ulcerative colitis, Celiac disease, Wegner's granulomatosis, Sclerosing cholangitis, Addison's disease, type 1 diabetes, rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis, Sjogren's syndrome,

lupus erythematosus, multiple sclerosis, myasthenia gravis, Retiter's syndrome and Grave's disease.

31. (New) A method for treating pain in a subject, comprising administering to the subject a therapeutically effective amount of secretin and a therapeutically effective amount of oxytocin.